

Breast Cancer Test Requisition

Phone: 866.776.5907 Fax: 239.690.4237 neogenomics.com

Last Name: Make Female	Client Information		Patient Information	
Account R:			Last Name:	□ Male □ Female
Date of Birth: rm (0) //wy Medical Record 9:				
Pione:				
Additional Reporting Fax: Paguidation Completed by Date: NP16:	Phone: Fax:			
Specimen Retrieval Clients practical practical practical processor price tast. Firsty Condening Physician: NPT #: Client Strates will request sport on the Peating Open Condition of Sportment (Page 1) and the Compensation of Sportment (Page 2) and the Compensation of Sportm	Additional Reporting Fax:		onent represents tenus obtained into	med donacht from patient to perform the services described herein.
Client Services will request specimen from Perhology site. Please fax this completed requisition, patholic gross open fax at First. Treating OncologistiPhysician: (gross open fax at First). The undersigned certifies that heidne is isoensed to order the test(s) isded below and that such test(s) are medically accessedy for the caverisement of this patient. Date: Date: Date: Date: Date: Dilling Information Required, Please include bees sheet and forerbook of patient's insurance cell. Sopicient Origin fund Consen 11: Sopicient Origin fu	Requisition Completed by:	Date:	O	
Treating Oncologist/Physician: The undersigned certifies that heise is licensed to order the test(s) listed below and that such test(s) are made only precessing for the care/breament of this patient. Date: Date:	Ordering Physician:	NPI #:	Specimen Retrieval	
Comments: Comm			Client Services will request speci	imen from Pathology site. Please fax this completed requisition, pathology
Address: Address: Address:	(please print: Last, First):			
Authorized Signature:	medically necessary for the care/treatment of this patient.			
Silling Information	Authorized Signature: Date:			
Required: Please include face sheet and front/back of patient's insurance and.				
Specimen Origin (haust Choose 1): Bill to: Client Bill Incorance Medical Patient (Self-Pay Hospital Patient (sut) Medical Patient (sut) Primary Metastasis. If Metastasis. I	_	ance card		
Hospital Patient (in)	Specimen Origin (Must Choose 1): Bill to: ☐ Client Bill		,	
Non-Topolal Patient See nacignos distinct including to more info.	☐ Hospital Patient (in) ☐ Medicare	☐ Medicaid ☐ Patient/Self-Pay	LI Primary Li Welastasis – II II	wetastasis, list Pililiary
Specimen ID: Spec	□ Non-Hospital Patient		Specimen Information	
Required. Please attach patient's pathology report (required), clinical history, and other applicable report(s). ICD 10 (Diagnosis) Code/Marrative (Required): Collection Date: mm	Prior Authorization # See neogenomics.com/billing for more info. Specimen ID:		Block ID:	
Retrieved Date: mm	Clinical Information			
Reason for Referral: Solid Tumor S: New Diagnosis Relapse in Remission Monitoring Solid Funds:	Required: Please attach patient's pathology report (required), clinical	history, and other applicable report(s).		
Solid Tumors: New Diagnosis Relapse In Remission Monitoring Staging: O II II IV Note: Primary Metastasis - If Metastas				
Primary Metastasis If Metastasias If Metastasia			· ·	
Predictive Marker Fixation (ACPIASCO Requirement): dindicated markers/profiles/panels require fixation information Cold ischemic duration (mins):				
S 1 hour Unknown Fixation duration (nims):	Predictive Marker Fixation (CAP/ASCO Requirement):		·	
Fixative: 10% NBF Other:			☐ FNA cell block:	
G - Global G-IA - Global with Image Analysis T - Tech-Only/Stain-Only T-IA - Tech-Only with Image Analysis T-SQnt - Tech-Only with Semi-Quantitative interpretation by client T-Qual - Tech-Only with Qualitative interpretation by client Tumor Testing FFPE Specimens Tumor Testing FFPE Specimens Tumor Testing FFPE Specimens Tumor Testing FFPE Specimens Consultation A NeoGenomics pathologist will select medically necessary tests (with any exception noted below by the client) to provide comprehensive analysis and professional interpretation for the materials submitted. Surgical Pathology Consult Add a 22C3 PD-L1 clone with CPS and TPS scoring [‡] Reflex to InVisionFirst [‡] -Lung Liquid Biopsy if tissue RNA and/or DNA is insufficient for NGS *PDL1 will report separately FISH G T HER2 Breast FISH panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal HER2 Breast FISH Tech-Only FISH T1 - Tech-Only IHC G TF TT HER2 Breast FISH Tesult is Group 2, 3, or 4 (see back) For global HER2 FISH Send path report. If HER2 IHC has been interpreted elsewhere: Send IHC report and also send HER2 IHC slide if result is 2+. D D Discovery Profile D Othor FISH: D D D D D Discovery Profile D D D D D D D D D D D	Fixative: 10% NBF Other:	Unknown		
T.SQnt - Tech-Only with Semi-Quantitative interpretation by client T.Qual - Tech-Only with Qualitative interpretation by client T.Qual - Tech-Only with Qualitative interpretation by client Tumor Testing Tumor Testing FFPE Specimens FFPE Specimens FFPE Specimens Tumor Testing FFPE Specimens FFPE Specimens FFPE Specimens FFPE Specimens Tumor Testing FFPE Specimens FFPE Speci	Fixation duration (hours):	🗖 6-72 hour 🗖 Unknown	☐ Paraffin Block(s) #:	☐ Choose best block (global testing only)
Neo Comprehensive A NeoGenomics pathologist will select medically necessary tests (with any exception noted below by the client) to provide comprehensive analysis and professional interpretation for the materials submitted. Surgical Pathology Consult Add NeoTYPE® Profile if indicated Differential Diagnosis: NeoTYPE® Profiles¹ *Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal □ G - Global TF - Tech-Only FISH TI - Tech-Only IHC G - FF Ti' B reast Tumor Profile HER2 IHC slide if result is 2+. Other FISH: Neo Comprehensive Neo Reflex to NFS 195 (set park 195 (set) Neo Type Profile indicated Neo Type Profile indi	T-SQnt - Tech-Only with Semi-Quantitative interpretation by client	nly T-IA - Tech-Only with Image Analysis	Comments:	
Neo Comprehensive A NeoGenomics pathologist will select medically necessary tests (with any exception noted below by the client) to provide comprehensive analysis and professional interpretation for the materials submitted. Surgical Pathology Consult Add NeoTYPE® Profile if indicated Differential Diagnosis: NeoTYPE® Profiles¹ *Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal □ G - Global TF - Tech-Only FISH TI - Tech-Only IHC G - FF Ti' B reast Tumor Profile HER2 IHC slide if result is 2+. Other FISH: Neo Comprehensive Neo Reflex to NFS 195 (set park 195 (set) Neo Type Profile indicated Neo Type Profile indi		Tue	or Tooting	FFOF O inv.
A NeoGenomics pathologist will select medically necessary tests (with any exception noted below by the client) to provide comprehensive analysis and professional interpretation for the materials submitted. Surgical Pathology Consult			ior resuing	
any exception noted below by the client) to provide comprehensive analysis and professional interpretation for the materials submitted. Surgical Pathology Consult			d Tumor	
□ Surgical Pathology Consult □ Add NeoTYPE® Profile if indicated □ Differential Diagnosis: □ NeoTYPE® Profiles* □ Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK □ HER2 Breast FISH □ □ HER2 Breast FISH □ □ Discovery Profile □ □ Breast Tumor Profile □ □ Discovery Profile □ □ BRCA1/2 Mutation Analysis for Tumors □ □ DISCOVERY PROFILE □ □	any exception noted below by the client) to provide comprehensiv	(tissue-based, DNA/RNA Profile with 51	7 genes + TMB/MSI in 10-days*)	
Surgical Pathology Consult	analysis and professional interpretation for the materials submitted		th CPS and TPS scoring [‡]	
Differential Diagnosis: NeoTYPE® Profiles* *Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal G - Global TF - Tech-Only FISH TI - Tech-Only IHC G TF TI" Breast Tumor Profile Breast Tumor Profile Discovery Profile BRCA1/2 Mutation Analysis for Tumors PDL1 Will report separately Reflex to HER2 Breast FISH: G T if HER2 IHC is: D DI + D D D D D D D D D	3	RNA and/or DNA is insuffici-		
NeoTYPE® Profiles* *Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal G - Global TF - Tech-Only FISH TI - Tech-Only IHC G TF TI" Near Time Discovery Profile				
NeoTYPE® Profiles‡ "Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal G - Global TF - Tech-Only FISH TI - Tech-Only IHC G TF Ti" NNA Precision Profile D iscovery Profile D iscovery Profile Primary Tumor:	Differential Diagnosis:			if HER2 IHC is: □ 0 □ 1+ □ 2+** □ 3+
*Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal *Reflex to HER2 IHC G-IA T-IA T if HER2 Breast FISH result is Group 2, 3, or 4 (see back) *For global HER2 FISH: Send path report. If HER2 IHC has been interpreted elsewhere: Send IHC report and also send HER2 IHC slide if result is 2+. Do not reflex	NeoTYPE® Profiles‡			**For global HER2 IHC with result 2+, NeoGenomics will add global HER2 Breast FISH unless marked here:
G - Global TF - Tech-Only FISH TI - Tech-Only IHC G TF TI" Breast Tumor Profile D ibscovery Profile* D ibscovery Profile* Primary Tumor: D Breast D Lung D Other For global HER2 FISH: Send path report. If HER2 IHC has been interpreted elsewhere: Send IHC report and also send HER2 IHC slide if result is 2+. D ibscovery Profile* Molecular BRCA1/2 Mutation Analysis for Tumors For global HER2 FISH: Send path report. If HER2 IHC has been interpreted elsewhere: Send IHC report and also send HER2 IHC (Breast) if global ER/PgR/HER2 panel is negative G T" D ip 53 D ip D-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast) if plots of TNBC (Br				
G TF TI" Been interpreted elsewhere: Send IHC report and also send HER2 IHC slide if result is 2+. HER2 IHC slide if result is 2+. Other FISH: Other FISH: Discovery Profile* Primary Tumor: Breast Lung Other BRCA1/2 Mutation Analysis for Tumors Discovery Profile* BRCA1/2 Mutation Analysis for Tumors	· ·			, ,
Breast Tumor Profile	,			. , , , , , , , , , , , , , , , , , , ,
Molecular Discovery Profile* Opt out of HER2 IHC Primary Tumor: Breast Lung Other BRCA1/2 Mutation Analysis for Tumors Discovery Profile* Opt out of HER2 IHC Primary Tumor: Breast Lung Other Discovery Profile* Opt out of HER2 IHC Opt out of HER2 I				
Primary Lumor: Li Breast Li Lung Li Ottner Li Li Brock 1/2 Multation Analysis for Tumors		Molecular		□ □ PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast)‡
	Primary Tumor: ☐ Breast ☐ Lung ☐ Other	☐ BRCA1/2 Mutation Analysis fo☐ EGFR	r Tumors	☐ ☐ PD-L1 LDT‡ ☐ ☐ Other IHC:
Reflex to HER2 (Other) w/Breast Reflex to HER2 (Other) w/Breast	, ,			and other mic.
Scoring FISH G T Other Molecular: "Tech-Only FDA PD-L1: Ordering Pathologist listed has received the required if global HER2 IHC is 0 0 1+	<u> </u>	☐ Other Molecular:		
□2+ (Default) □3+ Predictive / Recurrence Risk Profiles			k Profiles	competency training to perform the professional interpretation for this test
□ Do Not Reflex 2+ □ Breast Cancer Index® (BCI) [‡] Prediction of likelihood of benefit from extended endocrine therapy and FlexREPORT®	☐ Do Not Reflex 2+		from extended endocrine therapy and	FlexREPORT®
□ □ Other NeoTYPE: risk of late distant recurrence □ Please add summary report.	□ □ Other NeoTYPE:		·····	☐ Please add summary report.
Germline Testing Peripheral Blood. Consent Form Require		Germlir	e Testing	Peripheral Blood. Consent Form Required
□ BRCA1/2 Focus Panel (Germline)				
□ BRCA1 Single Gene (Germline) □ BRCA2 Single Gene (Germline) □ Full Comprehensive Cancer Panel (Germline) (127 genes) □ Full Focus Cancer Panel (Germline) (30 genes)	☐ BRCA2 Single Gene (Germline) ☐ Full Comprehensive Cancer Panel (Germline) (127 genes)			

Testing performed by Fulgent Genetics. A signed Fulgent Genetics Informed Consent for Genetic Testing form is REQUIRED. See test in NeoGenomics' Test Directory at www.neogenomics.com to download form and please submit it with sample.

Specimen Requirements

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call Client Services team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com/test-menu.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

Breast HER2, ER, PgR (IHC) and Breast HER2 (FISH)

Breast specimens undergoing any of these tests should be invasive breast cancer or the invasive component of the breast cancer fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 72 hours.

For global breast HER2 FISH cases, NeoGenomics will (if requested) reflex FISH to HER2 IHC if FISH results are consistent with CAP/ASCO 2018 result Groups 2, 3, or 4 for dual-probe ISH assays.

- Group 2: HER2/CEP17 ratio ≥ 2.0 and average HER2 copy number < 4.0 signals/cell
- Group 3: HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 6.0 signals/cell
- Group 4: HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 4.0 and < 6.0 signals/cell

If ordering global HER2 FISH after HER2 IHC was already interpreted outside NeoGenomics, please send the HER2 IHC result and the path report. If that IHC result was 2+, please submit the HER2-stained IHC slide to NeoGenomics with the FISH order so that we may correlate our analysis. This includes stain-only cases that were not scanned by NeoGenomics. If outside HER2 IHC results were other than 2+, we do not request the IHC slide but still request the HER2 IHC report.

Breast Cancer Index® (BCI)

For use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. Breast Cancer Index will be performed, reported and billed separately by Biotheranostics, Inc. For comprehensive details about Breast Cancer Index including test description, intended use and limitations, and Medicare Local Coverage Determination (LCD) criteria visit www.breastcancerindex.com

FlexREPORT®

FlexREPORT can be ordered on any global or tech-only testing referred to NeoGenomics. This report template can be used to import data and images collected from testing performed outside of NeoGenomics, and incorporated into a one page summary report. Client logo and contact information will be in the header of the FlexREPORT.